On Tuesday, medical device company NeuroMetrix, Inc. (NURO) said that it has reviewed strategic options for the growth of its Quell neuromodulation and DPNCheck neurodiagnostic businesses with maximum shareholder value.
The options include changes in marketing strategies, the acquisition of new assets, the potential sale of company assets, and merger or other strategic transactions, the company stated.
"We are also reviewing our DPNCheck business in light of the fundamental Medicare Advantage risk adjustment changes implemented by CMS last year", said Shai Gozani, CEO of NeuroMetrix. "We intend to continue carefully managing our liquid resources, optimizing cash flow and taking advantage of funding opportunities".
The company had engaged Ladenburg Thalmann & Co. as its financial advisor for assistance.
Currently, Neurometrix's stock is slipping 3.70 percent, to $3.25 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.